ArticleBlood advances2022

International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.

Farrukh T Awan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.